The orthotopic Fischer/AY-27 rat bladder urothelial cell carcinoma model to test the efficacy of different apaziquone formulations

Jemal, 2008, Cancer statistics, 2008, CA Cancer J Clin, 58, 71, 10.3322/CA.2007.0010 Kirkali, 2005, Bladder cancer: Epidemiology, staging and grading, and diagnosis, Urology, 66, 4, 10.1016/j.urology.2005.07.062 Sylvester, 2006, Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials, Eur Urol, 49, 466, 10.1016/j.eururo.2005.12.031 Hendriks, 1993, EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumor activity and lack of bone marrow toxicity in preclinical models, Eur J Cancer, 29A, 897, 10.1016/S0959-8049(05)80434-4 Schellens, 1994, Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug EO9, J Natl Cancer Inst, 86, 906, 10.1093/jnci/86.12.906 Pavlidis, 1996, A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: A study of the EORTC Early Clinical Studies Group (ECSG), Ann Oncol, 7, 529, 10.1093/oxfordjournals.annonc.a010645 Dirix, 1996, EO9 phase II study in advanced breast, gastric, pancreatic, and colorectal carcinoma by the EORTC Early Clinical Studies Group, Eur J Cancer, 32A, 2019, 10.1016/0959-8049(96)00226-2 Van der Heijden, 2006, Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: Toxicity and marker response, J Urol, 176, 1349, 10.1016/j.juro.2006.06.007 Puri, 2006, Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer, J Urol, 176, 1344, 10.1016/j.juro.2006.06.047 De Vries, 1993, A systematic study on the chemical stability of the novel indoloquinone antitumor agent EO9, Int J Pharm, 100, 181, 10.1016/0378-5173(93)90089-X Vainchtein, 2007, Stability experiments in human urine with EO9 (apaziquone): A novel anticancer agent for the intravesical treatment of bladder cancer, J Pharm Biomed Anal, 43, 285, 10.1016/j.jpba.2006.06.044 Abdallah, 2006, Analysis of NAD(P)H:quinone oxidoreductase-1 (NQO1), cytochrome P450 oxidoreductase (P450R) and glucose transporter 1 (Glut-1) protein expression suggests a possible role for EO9 in the treatment of invasive bladder cancer, Proc Am Assoc Cancer Res, 47, 546 Hendricksen, 2008, Evaluation of an orthotopic rat bladder urothelial cell carcinoma model by cystoscopy, BJU Int, 101, 889, 10.1111/j.1464-410X.2007.07407.x Xiao, 1999, Characterization of a novel transplantable orthotopic rat bladder transitional cell tumor model, Br J Cancer, 81, 638, 10.1038/sj.bjc.6690741 Oostveen, 1987, Mitomycin analogs I. Indoloquinones as (potential) bis-alkylating agents, Tetrahedron, 43, 255, 10.1016/S0040-4020(01)89952-X Loadman, 2000, Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice, Biochem Pharmacol, 59, 831, 10.1016/S0006-2952(99)00391-3 Au, 2001, Methods to improve efficacy of intravesical mitomycin C: Results of a randomized phase III trial, J Natl Cancer Inst, 93, 597, 10.1093/jnci/93.8.597 Beall, 1994, Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases, Cancer Res, 54, 3196 Boland, 1991, The differences in kinetics of rat and human DT-diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,3-dinitrobenzamide), Biochem Pharmacol, 41, 867, 10.1016/0006-2952(91)90190-G Gustafson, 2003, Kinetics of NAD(P)H:quinone oxidoreductase I (NQO1) inhibition by mitomycin C in vitro and in vivo, J Pharmacol Exp Ther, 305, 1079, 10.1124/jpet.103.050070